LAS VEGAS, June 3 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (Website: http://www.skinvisible.com), the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia. The Invisicare patent provides protection in the areas of “Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using”.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO
This patent will assist Skinvisible’s sales efforts in Australia by protecting its Invisicare technology and formulated products. Invisicare has a unique ability to hold active ingredients on the skin for extended periods of time while resisting wash-off, rub-off and perspiration. This benefit leads to additional unique enhancements to topical dermatology products. Additionally, Invisicare provides product life-cycle management by allowing for new patent protection for products coming off patent and providing improved claims to formulations of cosmetics, over-the-counter and prescription skincare products.
“The demand for our Invisicare technology and out products is international. A key component of our business strategy is to provide patentable products to our clients,” said Mr. Terry Howlett, President and CEO of Skinvisible. “Having our Invisicare patent approved in Australia is one more degree of protection that we can provide to our international licensees. We continue to submit for patent protection worldwide for all products formulated with Invisicare.”
Australia has followed India as the second international patent approved for Skinvisible. With numerous patents pending both for its technology and formulated products, Skinvisible continues to remain focused on securing licensees for its products internationally.
About Invisicare(R)
Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com
Forward-Looking Statements
This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007).
CONTACT: Terry Howlett, President-CEO of Skinvisible Pharmaceuticals,
Inc., +1-702-433-7154, info@skinvisible.com
Web site: http://www.skinvisible.com/
